Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Synthon Reports Positive Early Results with its Second Generation HER2-ADCs

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Best-in-class potential with improved therapeutic index compared to other armed antibodies.

Synthon Biopharmaceuticals has reported promising results with its lead program of antibody-drug conjugates (ADCs).

In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon has reported complete tumor remission.

Toxicity experiments conducted to-date have revealed Best-in-Class potential with a greatly improved therapeutic index compared to other armed antibodies, due to an impressive safety profile.

The company has also opened a GMP facility in Nijmegen for the production of ADCs up to phase III clinical trials and early launches.

ADCs are a new type of targeted therapy that combines a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

The aim for this class of therapy is to combine better tumor penetration and killing properties with lower side effects for cancer patients.

Dr. Marco Timmers, chief scientific officer at Synthon Biopharmaceuticals said: “Synthon’s first ADC program incorporates the HER2-binding antibody trastuzumab. The primary objective is to develop a broad therapeutic spectrum by targeting tumors that over-express HER2, such as metastatic breast cancer and non-small-cell lung cancer. As a result of our unique linker-drug technology, this ADC program is delivering on its promise and giving us exciting preclinical results with the opportunity to become a Best-in-Class therapy.”

In several xenograft models, including primary human breast cancer and non-small-cell lung cancer xenografts, Synthon’s HER2-ADC dosed alone induced complete tumor remission, whereas with the antibody alone there was no effect.

Toxicity studies conducted to-date have revealed that clinically effective doses are not likely to show serious side-effects since the difference between effective and toxic doses, the so-called therapeutic index, has been improved with at least one order of magnitude compared to competitor ADC technologies.

Synthon’s proprietary ADC linker-drug technology is based on duocarmycin analogs. The differentiating design of Synthon’s linker connecting the antibody to the duocarmycin drug, leads to high stability in circulation and also induces efficient release of the cytotoxin in the tumor cell.

A key feature of Synthon’s duocarmycin technology involves disruption of the DNA of (solid) tumor cells at any phase of the cellular cycle unlike many other ADCs which only attack tumor cells in a mitotic state.

Another feature of duocarmycins is that these cytotoxins can also be effective against tumor cells that are multi-drug resistant.

With the newly opened GMP facility available, Synthon will enter its drug candidate into clinical trials in 2014.

Dr. Timmers added: “We strongly believe that advancing this second generation ADC technology will lead to a new class of effective, targeted medicines in oncology. Our GMP plant will also accelerate future patient access to oncology products based on this pioneering technology.”

In addition to its ADC directed against HER2, Synthon is currently developing two other ADC programs for multiple indications in oncology.

Depending on the indication, projects will be progressed independently until registration or will be co-developed/licensed out at an appropriate (pre-)clinical stage.

Synthon also offers its linker-drug technology and manufacturing capabilities to external partners for conjugation to their own proprietary monoclonal antibodies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Synthon’s Anti-HER2 ADC Frontrunner SYD985 Outperforms HER2-targeting ADC
New treatment may broaden target population of cancer patients.
Thursday, April 03, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Genome of 6000-Year-Old Barley Sequenced
Researchers have successfully sequenced the genome of Chalcolithic barley grains for the first time.
3D Models May Yield Ovarian Cancer Insights
Researchers are developing new tools to decipher ovarian cancer developments through a 3D printing technology.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!